NCT03587311 2025-10-08Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting96 enrolled